The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is a flagship scheme of the central authorities. Archive | Photograph credit score: M. Moorthy
After Mauritius, now Nepal has approached India to determine Jan Aushadhi Kendras in that nation, which might allow its residents to profit from low-cost ‘Made in India’ generic medicines.
Earlier, Mauritius turned the primary nation to undertake the ‘Jan Aushadhi Plan’, enabling it to acquire round 250 high-quality medicines from India’s Bureau of Prescribed drugs and Medical Gadgets.
“Mauritius has now requested India to offer verification of 33 medication which might be a part of the Jan Aushadhi drug package deal. Moreover, Nepal has additionally proven curiosity in getting the ability,” a senior Well being Ministry official stated.
The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is a flagship scheme of the central authorities underneath which high quality generic medicines are supplied at reasonably priced costs by means of specialised retailers referred to as Pradhan Mantri Bharatiya Janaushadhi Kendras (PMBJK). India at the moment has greater than 10,000 PMBJKs throughout the nation.
The scheme is being applied by India’s Bureau of Prescribed drugs and Medical Gadgets, an autonomous company underneath the Division of Prescribed drugs.
A press launch from the central authorities stated that the scheme “goals to make high quality medicines and surgical gadgets out there to all at reasonably priced costs and thereby scale back the out-of-pocket bills of customers/sufferers and popularize generic medicines among the many lots.” .
“PMBJP’s product basket includes 1,965 medicines and 293 surgical kits protecting all main therapeutic teams corresponding to anti-infectives, anti-diabetics, cardiovascular, anti-cancer, gastrointestinal, and so on., which can be found on the market by means of these kendras. ” the press launch additionally states. In 2023, 206 drugs and 13 surgical tools had been added to the product basket.
The press launch added that in 2022-23, India’s Bureau of Prescribed drugs and Medical Gadgets recorded gross sales of Rs 1,235.95 crore, leading to financial savings of roughly Rs 7,416 crore for residents. Within the present monetary yr (2023-24), until November 30, 2023, the workplace had recorded gross sales of Rs 935.25 crore, leading to financial savings of roughly Rs 4,680 crore for residents. Within the final 9 years, in line with the press launch, roughly Rs 23,000 crore has been saved.
